We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced that Health Canada has granted a Notice of Compliance for its single-tablet regimen, Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), for the treatment of chronic hepatitis C virus (HCV) infection.
Vosevi has been approved for the treatment of HCV infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1, 2, 3 or 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor. The drug is already approved in the U.S.
Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. The HCV portfolio received a huge a boost when Epclusa gained approval in both the U.S. (Jun 2016) and EU (Jul 2016) to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection. The approval of Voseviwill further boost Gilead’s strong HCV portfolio.
However, the HCV franchise is under pressure as a result of competition and pricing issues. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie’s (ABBV - Free Report) Viekira Pak and Viekira XR and Bristol-Myers’ (BMY - Free Report) Daklinza among others. Competition as well as pricing pressure intensified further with the launch of Merck’s (MRK - Free Report) Zepatier.
Gilead’s stock has moved up 1.0% in the year so far compared with the industry’s gain of 7.3%.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU, which now represent 51% of total prescription volume. Genvoya is now the company’s bestselling HIV product with a treatment-naïve patient share of 41%. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting is expected to further boost sales. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which will impact sales.
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
Gilead Sciences, Inc. (GILD - Free Report) announced that Health Canada has granted a Notice of Compliance for its single-tablet regimen, Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), for the treatment of chronic hepatitis C virus (HCV) infection.
Vosevi has been approved for the treatment of HCV infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1, 2, 3 or 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor. The drug is already approved in the U.S.
Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. The HCV portfolio received a huge a boost when Epclusa gained approval in both the U.S. (Jun 2016) and EU (Jul 2016) to become the first and only all-oral, pan-genotypic, STR consisting of Sovaldi and velpatasvir (an NS5A inhibitor), for the treatment of adults with genotype 1-6 chronic HCV infection. The approval of Voseviwill further boost Gilead’s strong HCV portfolio.
However, the HCV franchise is under pressure as a result of competition and pricing issues. We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie’s (ABBV - Free Report) Viekira Pak and Viekira XR and Bristol-Myers’ (BMY - Free Report) Daklinza among others. Competition as well as pricing pressure intensified further with the launch of Merck’s (MRK - Free Report) Zepatier.
Gilead’s stock has moved up 1.0% in the year so far compared with the industry’s gain of 7.3%.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU, which now represent 51% of total prescription volume. Genvoya is now the company’s bestselling HIV product with a treatment-naïve patient share of 41%. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting is expected to further boost sales. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which will impact sales.
Zacks Rank
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>